Spoken Alpha
NewAmsterdam Pharma Co N.V.
NewAmsterdam Pharma develops obicetrapib, an oral CETP inhibitor drug candidate designed to lower LDL cholesterol in patients with cardiovascular disease or familial hypercholesterolemia who remain at elevated risk despite existing therapies.
NewAmsterdam Pharma Co N.V.
Behavioral analysis
Disclosures
Extracted from SEC 10-K filing, 2026-08-30.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add NAMSW, reply to your welcome email and we'll prioritize it.
History
Reported quarters with consensus, surprise, and 1-day reaction context.
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for NAMSW.
$ curl https://api.spokenalpha.com/v1/companies/NAMSWFAQ
Spoken Alpha indexes NAMSW's earnings call transcripts at https://spokenalpha.com/companies/NAMSW. Each call links to attributed speakers and parsed analyst Q&A. NewAmsterdam Pharma Co N.V.'s own investor relations page is at https://ir.newamsterdampharma.com/.